Primary bilateral non-Hodgkin’s lymphoma of the adrenal gland presenting as incidental adrenal masses by Rizzo, Christopher et al.
Case Report
Primary Bilateral Non-Hodgkin’s
Lymphoma of the Adrenal Gland Presenting as
Incidental Adrenal Masses
Christopher Rizzo,1,2 David James Camilleri,3 Alexandra Betts,4
Andre’ Gatt,5 and Stephen Fava1,2
1Diabetes and Endocrine Centre, Mater Dei Hospital, Msida MSD 2090, Malta
2Department of Medicine, University of Malta Medical School, Msida MSD 2080, Malta
3Department of Haemato-Oncology, Mater Dei Hospital, Msida MSD 2090, Malta
4Histopathology Section, Pathology Department, Mater Dei Hospital, Msida MSD 2090, Malta
5Medical Imaging Department, Mater Dei Hospital, Msida MSD 2090, Malta
Correspondence should be addressed to Christopher Rizzo; christopher.rizzo@um.edu.mt
Received 24 July 2015; Revised 19 October 2015; Accepted 26 October 2015
Academic Editor: Gerald S. Supinski
Copyright © 2015 Christopher Rizzo et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Although lymphoma may occasionally involve the adrenal glands as part of a generalized disease process, primary adrenal
lymphoma (PAL) is a rare disease. We present a case of a 62-year-old woman with a history of mild/moderate hereditary
spherocytosis with a well-compensated baseline haemoglobin, who presented with rapidly progressive symptomatic anaemia.
During the diagnostic workup, imaging revealed bilateral large adrenal masses and she was later diagnosed with diffuse large B-cell
non-Hodgkin’s lymphoma (DLBCL), with the adrenal glands being the dominant site of the disease. The patient was started on
systemic chemotherapy, but her disease progressed with neurological involvement which responded to second-line therapy. Her
adrenal disease however was refractory to further therapy.
1. Introduction
Malignant lymphoma arising primarily in the endocrine
organs is rare, accounting for less than 8% of extranodal
presentations, and among the endocrine organs, the thyroid
gland is most commonly involved [1].
PAL is a rare condition and may present as bilateral
adrenal masses which may be rapidly growing. Patients usu-
ally do not have disease elsewhere and this makes the diag-
nosis more difficult.
Symptoms of the disease are variable and patients are
most commonly older males. Presenting clinical features
include pyrexia, lumbar pain, and/or symptoms of adrenal
insufficiency. It may also be diagnosed incidentally on
abdominal imaging.
2. Case Presentation
A 62-year-old lady known to suffer from hereditary sphe-
rocytosis (HS) was referred to hospital with progressively
worsening symptomatic anaemia (Hb 7.7 g/dL), over a three-
week period.
She was afebrile and had a BP of 140/90mmHg. Exam-
ination of her cardiovascular and respiratory systems was
unremarkable. There was no palpable lymphadenopathy, but
splenomegaly, in keeping with her underlying diagnosis
of HS, was detected. There was no history of iatrogenic
immunosuppression or autoimmune disease.
A blood picture revealed spherocytosis and reticulocyto-
sis. An erythrocyte sedimentation rate (ESR) was raised at
100mm/h with a raised CRP of 15mg/L.
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Figure 1: CT of the abdomen showing bilateral, homogenous
adrenal gland enlargement.
Her urea and electrolytes were within normal limits.
Bilirubin was elevated at 22 umol/L (1.72–17.7), with normal
liver enzymes. Renal function, serum calcium, phosphate,
and albuminwere normal. A direct Coombs test was negative.
Serum ferritin was elevated at 487 ng/mL (10–291) with
normal serum iron andTIBC levels. Serum folate and vitamin
B12 levels were normal.
As part of her initial workup a CT, neck and trunk, was
performed, which revealed bilateral, marked, homogenous
adrenal gland enlargement (Figure 1), measuring 3.2 × 1.4 cm
on the right and 5.2 × 3.0 cm on the left, with concomitant
splenomegaly.
Serum and 24-hour urinary catecholamines and meta-
nephrines were not elevated. 24-hour urine cortisol levels
were within normal limits: 635 nmol/24 hours (57–806).
Serum cortisol at 09:00 h was 542 nmol/L (119–618).
Within a few weeks, whilst awaiting the adrenal biopsy,
our patient presented to hospital with nausea, vomiting, and
generalized aches and pains and new onset of submandibular
lymphadenopathy.
At this point investigations revealed a white blood cell
count of 4 × 109/L, haemoglobin 8.6 g/dL, and a platelet count
of 197 × 109/L with reticulocytosis. Urea and electrolytes
and creatinine were again within normal limits. Liver func-
tion tests revealed mild unconjugated hyperbilirubinemia
of 22.0 umol/L and a normal albumin and INR. The liver
enzymes were mildly deranged, alkaline phosphatase (ALP):
290U/L (40–104), alanine transaminase (ALT): 68U/L (5–
33), and gamma-glutamyl transferase (GGT): 104U/L (5–36).
Iron profile revealed a raised ferritin with normal iron levels,
as at initial presentation. Serum lactate dehydrogenase (LDH)
was elevated at 488U/L (135–250). Serumprotein electropho-
resis revealed elevated gamma globulin levels but no mon-
oclonal band. Tumour markers (carcinoembryonic antigen
andCA19-9)were negative andESRwas still raised at 114mm/
h (18–22), with a mildly raised CRP of 16mg/L (0–10).
Flouorordeoxyglucose positron emission tomography
(FDG PET) CT at this point revealed avid tracer uptake in
several pathologically enlarged lymph node groups above
and below the diaphragm, including both adrenal masses
(Figure 2), with the latter having more than doubled in size
from the CT at presentation and which now measured 7 ×
9 cm on the right and 8 × 12 cm on the left (Figure 3).
An excision biopsy of an axillary lymph node was per-
formed. The axillary lymph node was biopsied in preference
to an adrenal biopsy for logistical reasons.
Histology confirmed diffuse large B-cell lymphoma, acti-
vated B-cell phenotype (Figures 4 and 5).
Her international prognostic index (IPI) score [2] was
calculated at 4/5, based on her age (>60; +1), stage (IV; +1),
LDH (raised; +1), extranodal sites (×2; +1), and performance
status (1; 0). This put her in the high-risk category with a
median 5-year overall survival of ∼40%. Her bone marrow
was not involved at diagnosis.
3. Treatment
R-CHOP chemotherapy (rituximab, cyclophosphamide, dox-
orubicin, vincristine, and prednisolone) was initiated, but
despite clinical resolution of palpable lymphadenopathy after
2 cycles, she developed bilateral lower limb weakness and
paraesthesia.
MRI of the brain and spine did not reveal any evidence
of leptomeningeal disease or cord compression, but lumbar
puncture revealed a markedly raised cerebrospinal fluid
(CSF) protein 3054mg/L (150–600), with numerous blast-
like cells, compatible with involvement of CSF by lymphoma.
She was started on HyperCVAD/MA-R (hyperfraction-
ated cyclophosphamide, vincristine, doxorubicin, and dex-
amethasone alternating with high-dose methotrexate, cyto-
sine arabinoside, and rituximab), a regimen which includes
drugs which cross the blood-brain barrier, together with
intrathecal chemotherapy.
A repeat FDG PET-CT after 4 cycles of this regimen
revealed resolution of disease in all lymph node groups, a
clear CSF, but persistent disease in both adrenals, which did
notmeet criteria for partial remission by radiological criteria.
Biopsy of the adrenals at this stage was performed to exclude
a second concomitant pathology.The adrenal biopsy revealed
DLBCL of the activated B-cell phenotype (Figures 6, 7, 8, 9,
and 10).
At this point, in view of persistent disease, a decision was
made to change to third-line chemotherapy and work up the
patient for an autologous peripheral stem cell transplant.
The regimen chosen was R-GemCEBOM (rituximab,
gemcitabine, cyclophosphamide, etoposide, vincristine, and
methotrexate), which included intrathecal administration of
further chemotherapy and drugs she had not been exposed to
in previous regimens, namely, gemcitabine and etoposide.
This intensive weekly regimen was administered for the
duration of 12 weeks with full supportive measures, but some
delays were inevitable due to toxicity and neutropenic sepsis,
with ITU transfer occurring on two occasions, with the added
problem of hypoadrenalism due to adrenal infiltration.
Half-way through therapy, at 6 weeks, a restaging FDG
PET-CT revealed some reduction in adrenal disease, but an
end-of-treatment repeat scan showed further progression of
the adrenal masses.
At this point it was decided to go for a palliative
approach. Pulses of high-dose methylprednisolone together
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Figure 2: Fluorodeoxyglucose positron emission tomography demonstrating extensive uptake in both adrenal glands.
Figure 3: Spiral 64-slice CT scan obtained following intravenous
contrast (100mL Iohexol) in portovenous phase demonstrates
marked, homogenous bilateral adrenal gland enlargement with no
evidence of disease elsewhere.
with adrenal irradiation and pain relief were instituted. The
patient passed away 4 weeks following the institution of
palliative care and 1 year following initial diagnosis.
4. Discussion
PAL is a rare disorder [3, 4] and more common in men from
the sixth decade onwards [5]. The majority of cases involve
both adrenal glands and bulky disease is more common
[4].
The main clinical features are local symptoms such as
lumbar pain or systemic symptoms such as fever and weight
loss. Symptoms of adrenal insufficiency such as vomiting,
fatigue, skin hyperpigmentation, and hypotension can also
occur especially if there is extensive bilateral adrenal involve-
ment [6, 7]. Uncommon presentations include autoimmune
haemolytic anaemia [8], thrombocytopenia, decreased visual
acuity resulting from choroidal metastases [9], hypercal-
caemia [6], and concomitant involvement of other extranodal
sites. The exact pathogenesis is still unknown, although asso-
ciation with autoimmune diseases and immunodeficiency
states has been described [10]. Epstein-Barr virus (EBV) has
been associated with the development of endemic, sporadic,
and AIDS-associated Burkitt lymphoma. It has also been
described in the pathobiology of lymphoma in the setting of
immunosuppressive therapy, such as after organ transplan-
tation, or in the setting of chronic low-dose methotrexate
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Figure 4: Lymph node biopsy immunohistochemical staining
showing negative CD10 expression.
Figure 5: Lymph node biopsy immunohistochemical staining
showing MUM1 expression.
therapy, usually used in the treatment of rheumatic diseases
[11, 12].
Diagnosis can also be made incidentally on abdominal
imaging.
In the differential diagnosis of bilateral adrenal masses
one must consider metastatic deposits, bilateral phaeochro-
mocytoma, granulomatous disorders, and rarely adrenal
myelolipoma and adrenocortical carcinoma.
CT scan will generally show homogenous masses with
predominantly low density and slight to moderate enhance-
ment [4, 13]. These features are however not pathognomonic.
The most common histology in PAL is diffuse large B-
cell lymphoma, usually activated B-cell phenotype. T-cell and
angiocentric large cell lymphoma type B are the exception
[14].
Histological diagnosis is a gold standard in evaluation
of lymphoma. Prognosis is usually poor and the median
survival is usually less than 1 year [4, 15]. Poor prognostic
factors include advanced age, large tumour size, bilateral
Figure 6: H&E stain showing large atypical lymphoid cells with
apoptotic debris and mitotic figures (high power magnification).
Figure 7: Adrenal gland biopsy showing lymphoid cell positivity for
B-cell marker CD20.
Figure 8: Ki67 immunoperoxidase stain showing positive nuclear
staining of the lymphoma cells (Ki67 index ∼ 85%), indicating a high
proliferative rate.
involvement, high LDH levels, involvement of other organs,
and initial presentation with adrenal insufficiency [2, 4].
The germinal centre subtype (GCB) seems to have a better
prognosis than the non-GCB subtype [16]. CNS involvement
worsens long-term prognosis and the addition of rituximab
has significantly improved outcomes in PAL [13].
PAL usually does not have disease found elsewhere, but
if it is present, it is more likely extranodal in nature. Sites
for extranodal involvement for PAL are the CNS and the
gastrointestinal tract, as well as other endocrine organs [3].
In PAL, disease may also relapse in the CNS and the risk of
CNS relapse may be high [4].
The therapeutic modalities include combination chemo-
therapy and radiotherapy in order to prevent local recur-
rence. Surgical debulking is not recommended in view of
Case Reports in Medicine 5
Figure 9: Adrenal biopsy immunohistochemical staining showing
negative CD10 expression.
Figure 10: Adrenal biopsy immunohistochemical staining showing
positive MUM1 expression.
high morbidity and mortality and recurrence of the disease
elsewhere later [4].
In conclusion, this rare disease entity has to be consid-
ered in the differential diagnosis of endocrinologically silent
adrenal masses, especially if bilateral or rapidly growing.
The diagnosis is essentially histological and this highlights
the importance of obtaining a tissue biopsy early on in the
diagnostic workup of bilateral adrenal masses. PAL is an
aggressive type of DLBCL, and prognosis is generally quite
poor [13, 16]. The most appropriate therapeutic approach has
not been identified, due to the lack of randomized controlled
trials, with this being a rare disorder.
5. Learning Points/Take-Home Messages
(1) Primary adrenal lymphomas are rare tumours.
(2) PAL should be considered in the differential diagnosis
of unilateral and bilateral adrenal masses.
(3) Patients may present with clinical features of adrenal
insufficiency.
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